Quick SARS-CoV-2 Multiplex Kit

(For COVID-19 Detection)

FDA EUA and CE-IVD Quick SARS-CoV-2 Multiplex Kit product photo
The Quick SARS-CoV-2 Multiplex Kit is a second-generation RT-PCR test for COVID-19 detection developed by Zymo Research.

Reliable, Affordable Testing Solutions for COVID-19

The Quick SARS-CoV-2 Multiplex Kit is a highly sensitive and specific molecular test with improved throughput capability. The ready-to use reagents and the competitive pricing make the Quick SARS -CoV-2 Multiplex Kit the test of choice for any laboratory. The Quick SARS-CoV-2 Multiplex Kit is CE-IVD marked. Zymo Research plans on submitting an FDA EUA application for the Quick SARS-CoV-2 Multiplex Kit and workflow for SARS-CoV-2 virus and COVID-19 detection.

Sensitivity

Extremely sensitive, with 100% viral detection at 10 GEC/reaction (167 GEC/ml of sample).

Specificity

Specific detection of SARS-CoV-2. No cross-reactivity with other pathogens and viruses.

Controls

Robust control system that minimizes false negative results.

Simplicity

Ready-to-use reagents for simple set-up and minimal hands-on time. Results are generated in less than 2 hours.

Competitive Pricing

Affordable solution for every laboratory to allow better COVID-19 testing.

Flexibility

Compatible with Real-Time PCR instrumentation capable of detecting HEX/VIC and Quasar670/Cy5 fluorophores.*

Intended Use

Quick SARS-CoV-2 Multiplex Kit is a real-time RT-PCR test intended for the qualitative detection of nucleic acids from SARS-CoV-2 in upper respiratory specimens (such as nasal, nasopharyngeal, mid-turbinate or oropharyngeal swabs), and lower respiratory specimens (such as sputum, tracheal aspirates, and bronchoalveolar lavage) from patients suspected of COVID-19 by medical personnel. Testing is limited to diagnostic laboratories certified by health authorities to perform high complexity tests.

The test is intended for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in upper and lower respiratory specimens during the acute phase of infection.

Positive results are indicative of the presence of SARS-CoV-2 RNA. Clinical observations, patient history and other diagnostic information are necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

The Quick SARS-CoV-2 Multiplex Kit should be used by laboratory personnel trained in the techniques of real-time RT-PCR assays.

Learn More About Zymo Research’s COVID-19 Solutions

Sample Collection in DNA/RNA Shield
Shield Swab and Saliva Collection

Proprietary sample collection technology

  • Store the sample at ambient temperature up to 7 days.
  • No cold-chain required for shipping.
  • Collection devices for upper and lower respiratory tract specimens.
RNA Extraction Using Quick-DNA/RNA Viral Magbead Kit
Direct-zol RNA Microprep Kits

Robust nucleic acid purification

  • Compatible with manual and automated procedures.
  • Automated RNA extraction in < 1 hour using the KingFisher™ Flex Purification System (ThermoFisher Scientific).
SARS-CoV 2 Detection Using the Quick SARS-CoV-2 rRt-PCR Kit
Quick SARS-CoV-2 Kit

SARS-CoV-2 detection system

  • Simple reaction set-up.
  • 100% detection at 15 GEC/rxn.
  • Results in < 1.5 hours after extraction.
  • Includes CV Mix 1 (for SARS-CoV-2 detection), CV Mix 2 (internal human control), CV Positive Control and No Template Control.

*Adjustments of RT-PCR parameters may be necessary.

This test has not been FDA cleared or approved.